<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37485770</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Systemic lupus erythematosus complicated with cardiovascular disease.</ArticleTitle><Pagination><StartPage>1429</StartPage><EndPage>1431</EndPage><MedlinePgn>1429-1431</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.14741</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ke-Qu</ForeName><Initials>KQ</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Guilin Medical University, Guilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Zhen-Zhen</ForeName><Initials>ZZ</Initials><Identifier Source="ORCID">0000-0003-1001-2817</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Guilin Medical University, Guilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Si-Ru</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-4437-6742</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Guilin Medical University, Guilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Hua-Song</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0002-7166-0941</Identifier><AffiliationInfo><Affiliation>Department of Pediatric Allergy, Immunology &amp; Rheumatology, Women and Children's Medical Center, Guanzhou Medical University, Center and South National Pediatric Medical Center, Guanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Han-You</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0001-5482-5014</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, The Affiliated Hospital of Guilin Medical University, Guilin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Guangxi Natural Science Foundation (Grant number 2021GXNSFAA220006)</Agency><Country/></Grant><Grant><Agency>National Natural Science Foundation of China (Grant number 81760298)</Agency><Country/></Grant><Grant><Agency>the 139 Program for the High-Level Medical Talents in Guangxi Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37485770</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14741</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ahn GY, Lee J, Won S, et al. Identifying damage clusters in patients with systemic lupus erythematosus. Int J Rheum Dis. 2020;23(1):84-91. doi:10.1111/1756-185x.13745</Citation></Reference><Reference><Citation>Li M, Wang Y, Zhao J, et al. Chinese SLE treatment and research group (CSTAR) registry 2009-2019: major clinical characteristics of Chinese patients with systemic lupus erythematosus. Rheumatol Immunol Res. 2021;2(1):43-47. doi:10.2478/rir-2021-0001</Citation></Reference><Reference><Citation>Etchegaray-Morales I, Mendoza-Pinto C, Munguia-Realpozo P, et al. Systemic lupus erythematosus, a leading cause of death in young Mexican females: a nationwide population-based study, 2000-2020. Rheumatol Int. 2022;42(10):1715-1720. doi:10.1007/s00296-022-05154-9</Citation></Reference><Reference><Citation>Ugarte-Gil MF, Alarcon GS, Izadi Z, et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology Alliance. Ann Rheum Dis. 2022;81(7):970-978. doi:10.1136/annrheumdis-2021-221636</Citation></Reference><Reference><Citation>Ci W, Zhao J, Qi W, et al. Characteristics and Risk Factors of Severe Coronary Artery Disease in Systemic Lupus Erythematosus: A Multicenter, Chinese Rheumatism Date Center database study. Int J Rheum Dis. 2022;25(10):1186-1195. doi:10.1111/1756-185x.14402</Citation></Reference><Reference><Citation>Wilhelm AJ, Rhoads JP, Wade NS, Major AS. Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr&#x2212;/&#x2212; mice. Ann Rheum Dis. 2015;74(4):778-785. doi:10.1136/annrheumdis-2013-203759</Citation></Reference><Reference><Citation>Zhu M, Mo H, Li D, Luo X, Zhang L. Th17/Treg imbalance induced by increased incidence of atherosclerosis in patients with systemic lupus erythematosus (SLE). Clin Rheumatol. 2013;32(7):1045-1052. doi:10.1007/s10067-013-2237-z</Citation></Reference><Reference><Citation>Spinosa MD, Montgomery WG, Lempicki M, et al. B cell-activating factor antagonism attenuates the growth of experimental abdominal aortic aneurysm. Am J Pathol. 2021;191(12):2231-2244. doi:10.1016/j.ajpath.2021.08.012</Citation></Reference><Reference><Citation>Saidoune F, Even G, Lamri Y, et al. Effects of BAFF neutralization on atherosclerosis associated with systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(2):255-264. doi:10.1002/art.41485</Citation></Reference><Reference><Citation>Zhu ZZ, Chen XH, Wei SR, et al. Role of CD19(+) CD5(+) CD1d(+) Bregs in maintaining the Th17/Treg balance in mice with systemic lupus erythematosus complicated with atherosclerosis. Int J Rheum Dis. 2023. doi:10.1111/1756-185x.14691</Citation></Reference><Reference><Citation>Nikolova-Ganeva K, Vasilev V, Kerezieva S, Tchorbanov A. Impact of folic acid on regulatory B lymphocytes from patients with systemic lupus erythematosus in vitro. Int J Rheum Dis. 2023;26(2):298-304. doi:10.1111/1756-185x.14496</Citation></Reference><Reference><Citation>Chanloung W, Kasitanon N, Wichainun R, Louthrenoo W. Thrombotic risk assessment in patients with systemic lupus erythematosus: validation of the adjusted-global antiphospholipid syndrome score (aGAPSS) in Thai patients. Int J Rheum Dis. 2021;24(12):1510-1519. doi:10.1111/1756-185x.14230</Citation></Reference><Reference><Citation>Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med. 2017;4(1):e000239. doi:10.1136/lupus-2017-000239</Citation></Reference><Reference><Citation>Bandhan IH, Islam MN, Ahmad HI, Ahmedullah AK. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. Int J Rheum Dis. 2022;25(2):121-130. doi:10.1111/1756-185x.14265</Citation></Reference><Reference><Citation>Hsu CY, Lin YS, Su YJ, et al. Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study. Rheumatology (Oxford). 2017;56(12):2212-2221. doi:10.1093/rheumatology/kex357</Citation></Reference><Reference><Citation>Hasni S, Temesgen-Oyelakin Y, Davis M, et al. Peroxisome proliferator activated receptor-&#x3b3; agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus. Ann Rheum Dis. 2022;81(11):1576-1584. doi:10.1136/ard-2022-222658</Citation></Reference><Reference><Citation>Aprahamian TR, Bonegio RG, Weitzner Z, Gharakhanian R, Rifkin IR. Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. Immunology. 2014;142(3):363-373. doi:10.1111/imm.12256</Citation></Reference><Reference><Citation>Casey KA, Smith MA, Sinibaldi D, et al. Modulation of Cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(3):459-471. doi:10.1002/art.41518</Citation></Reference><Reference><Citation>Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi:10.1038/s41467-021-23361-z</Citation></Reference><Reference><Citation>Petri M, Bruce IN, Dorner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401(10381):1011-1019. doi:10.1016/s0140-6736(22)02546-6</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>